Overview

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Evaluate the effect of multiple doses (once daily for 3 days each of HYD 80, 120, and 160 mg tablets) on the QT/QTc interval.
Phase:
Phase 1
Details
Lead Sponsor:
Purdue Pharma LP
Treatments:
Fluoroquinolones
Hydrocodone
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination